STELLAR, 'Impressive' Results With Novel Drug Sotatercept in PAH
The randomized trial of this first-in-class injectable drew sustained applause at ACC 2023 when results were presented.
Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The randomized trial of this first-in-class injectable drew sustained applause at ACC 2023 when results were presented.
(Reuters) -Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease th...
Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission
The global Eisenmenger complex management market is expected to surpass an impressive valuation of US$ 7.7 billion in 2023 and is projected to reach US$ 12.9 billion by 2033, growing at a CAGR of 5.3%. Generally, the treatment includes relieving the symptoms and associated co-morbidities. Medications such as calcium...
RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology’s 72nd Annual Scientific Session toget...